Table 3. Clinical characteristics of recurrent HCC in the propensity score-matched groups.
| Variables | LAR (N=46) | LNAR (N=46) | P value |
|---|---|---|---|
| Recurrence, n (%) | 14 (30.4) | 14 (30.4) | 1.000 |
| Recurrence site, n (%) | 0.023 | ||
| Intrahepatic | 8 (57.1) | 11 (78.6) | |
| Right lobe | 2 | 11 | |
| Left lobe | 6 | 0 | |
| Extrahepatic | 5 (35.7) | 1 (7.1) | |
| Both | 1 (7.1) | 2 (14.3) | |
| Time to recurrence, n (%) | 0.695 | ||
| Early recurrence (≤24 months) | 6 (42.9) | 5 (35.7) | |
| Late recurrence (>24 months) | 8 (57.1) | 9 (64.3) | |
| Treatment after recurrence, n (%) | 0.016 | ||
| Curative intent treatment | |||
| Re-resection | 0 | 5 (35.7) | |
| RFA | 1 (7.1) | 3 (21.4) | |
| RFA + TACE | 3 (21.4) | 0 | |
| Palliative treatment | |||
| TACE | 2 (14.3) | 3 (21.4) | |
| Chemotherapy or supportive therapy | 8 (57.1) | 3 (21.4) |
HCC, hepatocellular carcinoma; LAR, laparoscopic anatomical resection; LNAR, laparoscopic non-anatomical resection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.